Rush University Medical Center 2nd Midwest Cellular Conference Treatment Options for Advanced Hematologic Malignancies 2022
Format: 22 videos, size: 5 GB
Course Audience: hematologists, medical oncologists, pharmacists
Overview:
Treatment options for relapsed/refractory (advanced) hematologic malignancies have progressed rapidly in only the last decade. Development of revolutionary treatment options, including CAR T-cell therapy, novel immunotherapies, and novel chemotherapeutic agents has only accelerated since the first product targeting CD19 was developed in 2003. These developments provide excellent opportunities for patients, and with opportunities arrive challenges for clinicians in maintaining optimal approaches to care. To address the educational need the 2nd Midwest Cellular Conference: Treatment Options for Advanced Hematologic Malignancies is planned . This activity will engage an interprofessional audience of learners with important updates in hematologic oncology that are provided at the annual Transplantation and Cellular Therapy (TCT) meeting organized in February 2022, and at the American Society of Hematology (ASH) in December 2021. As an added benefit, a half-day pre-conference entitled Women in Cell Therapy will be provided.
This program is designed to meet the educational needs of hematologists, medical oncologists, pharmacists, fellows and residents, APP’s, oncology nurses and other healthcare professionals committed to the field of cellular treatment options for advanced hematologic malignancies.
LEARNING OBJECTIVES
Following participation in this activity, learners will:
- Discuss individualized treatment options for high-risk patients with diffuse large B-cell lymphoma (DLBCL), Hodgkins lymphoma (HL), non-Hodgkin Lymphoma (NHL), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
- Include autologous or allogeneic HCT and/or CAR T-cell therapy in treatment plans for patients with various refractory (advanced) hematologic malignancies.
- Manage potential complications resulting from autologous or allogeneic HCT and/or CAR T-cell therapy.
- Utilize newer chemotherapeutic treatment options in conjunction with HCT and CAR T-cell therapy for patients with various refractory (advanced) hematologic malignancies.
- Discuss the role of gender in the management and treatment of various hematologic conditions
Alternative Allogeneic Transplant Donors- How These Are Changing the Landscape (Video MP4 Format)
APPs in Cellular Therapy (Video MP4 Format)
CAR T-Cells in Pediatrics (Video MP4 Format)
Cardio-Oncology in Cell Therapy (Video MP4 Format)
Failure After CAR T-Cell Therapy in Lymphoma- What To Do Next (Video MP4 Format)
Gene Therapy in Sickle Cell Disease (Video MP4 Format)
HaploSCT- Choosing an Optimal Donor and Novel Strategies to Mitigate Post HaploSCT Relapse and Improve Immune Reconstitution (Video MP4 Format)
High-Risk Myeloma- Failures and Future Directions (Video MP4 Format)
Hodgkin Lymphoma- Managing Brentuximab Vedotin CPI Dual Refractory Patients (Video MP4 Format)
Immunotherapy in MM- Beyond CAR-T (Video MP4 Format)
Improving Neutropenic Fever Strategies (Video MP4 Format)
Mantle Cell Lymphoma Management After AutoHCT Relapse (Video MP4 Format)
Myelofibrosis- Novel Agents and HCT (Video MP4 Format)
Novel Agents for MDS (Video MP4 Format)
Novel Therapies for Relapsed AML (Video MP4 Format)
Pharmacy in Cellular Therapy (Video MP4 Format)
Post-HCT Relapse Prevention in Myeloid Malignancies (Video MP4 Format)
RR Follicular Lymphoma- Novel Agent, Transplant, or CAR T-Cells (Video MP4 Format)
Thrombotic Microangiopathies- Modern Diagnosis and Treatments (Video MP4 Format)
Update on CAR-T Therapy for Multiple Myeloma (Video MP4 Format)
Upfront Autologous Transplant in Multiple Myeloma (Video MP4 Format)
Work-Life Balance- Avoiding Burnout (Video MP4 Format)